Corneal transplantation and infectious hepatitis

Corneal tissue is not usually taken from persons with signs of viral hepatitis at the time of death. The viruses responsible are highly infectious and the procedure would be considered hazardous both to the recipient of the cornea and to eye bank personnel. The hepatitis A and E viruses are transmitted principally by the faecal–oral route, have a relatively brief viraemic phase, and do not persist after recovery from illness. Hepatitis D virus (HDV) can persist, but is able only to multiply in cells that are co-infected with hepatitis B virus (HBV). The two agents of particular concern in transplantation are HBV and hepatitis C virus (HCV) because of their ability to persist in some individuals for years after resolution of symptoms. The blood of most HBV carriers has a high titre of infectious particles.\(^1\) Acute infection with either virus can result in cirrhosis and chronic infection is associated with liver cancer. As testing donors for HBV and HCV is a significant component of an eye bank’s budget, what evidence is there that it is necessary?

The medical standards published by the Eye Bank Association of America (EBAA) have been the benchmark for eye bank practice.\(^2\) The contraindications listed for eye donation include evidence for infectious diseases or their agents known to have been transmitted to recipients by corneal transplantation, such as Creutzfeldt-Jakob disease\(^3\) and rabies,\(^4,5\) or suspected of having this potential, such as syphilis, rubella, and the human T cell leukaemia viruses. HBV is in the first category and HCV and human immunodeficiency virus type 1 (HIV-1) are in the second. Although three corneas from two HIV-1 seropositive donors and two from seronegative ‘window period’ donors\(^6\) are known to have been transplanted, the recipients did not seroconvert and remained healthy. They may have been fortunate as Qavi \textit{et al.}\(^7\) were able to culture HIV-1 from corneal specimens of two of 35 asymptomatic HIV-1 carriers and two of 10 AIDS patients. Suspicions as to the possible transmission of HBV by corneal transplantation were raised following the detection of surface antigen (HBsAg), an indicator of active infection, in corneal tissue of carriers.\(^10,11\) In one report, three patients received corneas from HBsAg seropositive donors but remained free from disease.\(^11\) One patient was given specific immunoglobulin, another received immunoglobulin and HBV vaccine, and the third had existing anti-HBV antibody. However, two cases of hepatitis B almost certainly transmitted by corneal grafts were presented at the American Academy of Ophthalmology Annual Meeting in 1988 by Hoft \textit{et al.}\(^8\) This prompted the EBAA requirement for HBsAg serology on all corneal donors.

In Western countries, positive HBV serology is a relatively infrequent reason for withholding eye bank material. This is due to the low prevalence of HBV carriage (\(<1\%\)) and the donor exclusion criteria in place to counter HIV-1. In regions of high carriage, however, the loss of otherwise useful tissue can be significant. For example, the prevalence of HBsAg seropositivity in Cairo has been given as 6-2-12\(^\text{\textsuperscript{12}}\) and a similar study carried out in the UK reports a prevalence of 16-4\(^\text{\textsuperscript{12}}\) in the local population.

1. Scullard GH, Greenberg HB, Smith JL, Gregory PB, Merigan TC, Robinson WS. Antiviral treatment of chronic hepatitis B virus infection: The medical standards published by the Eye Bank Association of America (EBAA) have been the benchmark for eye bank practice. The contraindications listed for eye donation include evidence for infectious agents known to have been transmitted to recipients by corneal transplantation, such as Creutzfeldt-Jakob disease and rabies, or suspected of having this potential, such as syphilis, rubella, and the human T cell leukaemia viruses. HBV is in the first category and HCV and human immunodeficiency virus type 1 (HIV-1) are in the second. Although three corneas from two HIV-1 seropositive donors and two from seronegative ‘window period’ donors are known to have been transplanted, the recipients did not seroconvert and remained healthy. They may have been fortunate as Qavi \textit{et al.}\ were able to culture HIV-1 from corneal specimens of two of 35 asymptomatic HIV-1 carriers and two of 10 AIDS patients. Suspicions as to the possible transmission of HBV by corneal transplantation were raised following the detection of surface antigen (HBsAg), an indicator of active infection, in corneal tissue of carriers. In one report, three patients received corneas from HBsAg seropositive donors but remained free from disease. One patient was given specific immunoglobulin, another received immunoglobulin and HBV vaccine, and the third had existing anti-HBV antibody. However, two cases of hepatitis B almost certainly transmitted by corneal grafts were presented at the American Academy of Ophthalmology Annual Meeting in 1988 by Hoft \textit{et al.}\ This prompted the EBAA requirement for HBsAg serology on all corneal donors.

In Western countries, positive HBV serology is a relatively infrequent reason for withholding eye bank material. This is due to the low prevalence of HBV carriage (\(<1\%\)) and the donor exclusion criteria in place to counter HIV-1. In regions of high carriage, however, the loss of otherwise useful tissue can be significant. For example, the prevalence of HBsAg seropositivity in Cairo has been given as 6-2-12\(^\text{\textsuperscript{12}}\) and a similar study carried out in the UK reports a prevalence of 16-4\(^\text{\textsuperscript{12}}\) in the local population.
Corneal transplantation and infectious hepatitis.

P R Badenoch

*Br J Ophthalmol* 1995 79: 2
doi: 10.1136/bjo.79.1.2

Updated information and services can be found at:
http://bjo.bmj.com/content/79/1/2.citation

Email alerting service

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/